专题：HER2/EGFR in Cancer Research

This cluster of papers focuses on the use of HER2-targeted therapies, such as trastuzumab and pertuzumab, in the treatment of HER2-positive breast cancer. It explores the mechanisms of action, resistance, and combination therapies involving chemotherapy and monoclonal antibodies. The cluster also delves into the role of EGFR, neuregulin 1, and ADAM metalloproteinases in HER2 signaling and breast cancer progression.
最新文献
Exploring the next generation of antibody–drug conjugates

review Full Text OpenAlex

Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II

review Full Text OpenAlex

Antibody-drug conjugates in cancer therapy: applications and future advances

review Full Text OpenAlex

Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer

review Full Text OpenAlex

Rational and trial design of FASCINATE-N: a prospective, randomized, precision-based umbrella trial

article Full Text OpenAlex

The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial

article Full Text OpenAlex

The Clinicopathological and Prognostic Significance of HER2-Low Breast Cancer: A Comparative Analysis Between HER2-Low and HER2-Zero Subtypes

article Full Text OpenAlex

Development of Erlotinib-Loaded Nanotransferosomal Gel for the Topical Treatment of Ductal Carcinoma in Situ

article Full Text OpenAlex

Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2− Breast Cancer

review Full Text OpenAlex

A prospective comparison study utilizing patient-reported outcomes of taxane-related peripheral neuropathy between nab-paclitaxel and standard paclitaxel in patients with breast cancer

article Full Text OpenAlex

近5年高被引文献
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

article Full Text OpenAlex 2157 FWCI322.0616709

Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer

article Full Text OpenAlex 1671 FWCI164.5288604

Breast cancer

review Full Text OpenAlex 1432 FWCI207.1185657

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

article Full Text OpenAlex 1296 FWCI100.32373936

Antibody drug conjugate: the “biological missile” for targeted cancer therapy

review Full Text OpenAlex 1264 FWCI189.18516283

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

article Full Text OpenAlex 1145 FWCI145.38980445

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

article Full Text OpenAlex 975 FWCI132.55760298

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

article Full Text OpenAlex 969 FWCI144.94264838

Kinase drug discovery 20 years after imatinib: progress and future directions

review Full Text OpenAlex 948 FWCI142.58391616

Unlocking the potential of antibody–drug conjugates for cancer therapy

review Full Text OpenAlex 944 FWCI76.42215882